Anna Maria Militello

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Umberto Peretti · 5 shared papers, 2021–2023 · strength 0.65
   • Paper Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic duc… DOI 10.1016/j.ctrv.2022.102357↗
   • Paper Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variant… DOI 10.1016/j.ctrv.2021.102262↗
   • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
2. Marina Macchini · 5 shared papers, 2021–2023 · strength 0.65
   • Paper Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic duc… DOI 10.1016/j.ctrv.2022.102357↗
   • Paper Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variant… DOI 10.1016/j.ctrv.2021.102262↗
   • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
3. Giulia Orsi · 5 shared papers, 2021–2023 · strength 0.65
   • Paper Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic duc… DOI 10.1016/j.ctrv.2022.102357↗
   • Paper Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variant… DOI 10.1016/j.ctrv.2021.102262↗
   • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
4. Michele Reni · 5 shared papers, 2021–2023 · strength 0.65
   • Paper Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic duc… DOI 10.1016/j.ctrv.2022.102357↗
   • Paper Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variant… DOI 10.1016/j.ctrv.2021.102262↗
   • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
5. Stefano Cascinu · 5 shared papers, 2021–2023 · strength 0.65
   • Paper Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic duc… DOI 10.1016/j.ctrv.2022.102357↗
   • Paper Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variant… DOI 10.1016/j.ctrv.2021.102262↗
   • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
6. Elisa Giommoni · 3 shared papers, 2021–2023 · strength 0.35
   • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
   • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
7. Silvia Bozzarelli · 3 shared papers, 2021–2023 · strength 0.35
   • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
   • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
8. Guido Giordano · 3 shared papers, 2021–2023 · strength 0.35
   • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
   • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
9. Ilario Giovanni Rapposelli · 3 shared papers, 2021–2023 · strength 0.35
   • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
   • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
   • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
10. Monica Niger · 3 shared papers, 2021–2023 · strength 0.35
    • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
11. Giampaolo Tortora · 3 shared papers, 2021–2023 · strength 0.35
    • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
12. Michèle Milella · 3 shared papers, 2021–2023 · strength 0.35
    • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
13. Letizia Procaccio · 2 shared papers, 2023 · strength 0.26
    • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
14. Lisa Salvatore · 2 shared papers, 2023 · strength 0.26
    • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
15. Mario Scartozzi · 2 shared papers, 2021–2023 · strength 0.21
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
16. Andrea Spallanzani · 2 shared papers, 2021–2023 · strength 0.21
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
17. Maria Grazia Rodriquenz · 2 shared papers, 2021–2023 · strength 0.21
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
18. Mariacristina Di Marco · 2 shared papers, 2021–2023 · strength 0.21
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
19. Alessandro Bittoni · 2 shared papers, 2021–2023 · strength 0.21
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
20. Ingrid Garajová · 2 shared papers, 2021–2023 · strength 0.21
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
21. Antonio Avallone · 1 shared paper, 2023 · strength 0.14
    • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
22. Alberto Puccini · 1 shared paper, 2023 · strength 0.14
    • Paper Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unkn… DOI 10.1007/s00280-023-04585-w↗
23. Sara Lonardi · 1 shared paper, 2023 · strength 0.12
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
24. Enrico Vasile · 1 shared paper, 2023 · strength 0.12
    • Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
25. Stefania Mosconi · 1 shared paper, 2021 · strength 0.09
    • Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.